Introduction
Until the 1960s, the chemotherapy of human intestinal and systemic helminthiases was extremely unsatisfactory;' piperazine compounds, bephenium hydroxynaphthoate and pyrantel embonate were, for example, widely used for the former, and diethylcarbamazine (DEC), niridazole, and bithionol for the latter. Table I summarizes some important agents which have recently become available. The first of the benzimidazole compounds, thiabendazole (which had formerly been widely used in veterinary medicine and which has many undesirable side effects) was introduced into clinical medicine in the early 1960s; others soon followed, and the most recently introduced is albendazole. This group of compounds is of value in the management of many intestinal and systemic nematode infections.24 Praziquantel (introduced during the 1970s) has proved of immense value in many cestode and trematode (fluke) infections; numerically it has been most extensively used in the human schistosomiases.2'3'5'6 Ivermectin, which had also been widely used in veterinary medicine first became available in clinical medicine in the early 1 980s;78 as well as being effective in a wide range of intestinal nematode infections it has proved to be a valuable and safe microfilaricidal agent in onchocerciasis (see below).
In addition to these 3 agents, oxamniquine and metriphonate have been introduced into clinical medicine for Schistosoma mansoni and S. haematobium infections, respectively (see below). They have the advantage that in most countries they are cheaper than praziquantel; however, both are species specific and the latter compound is often cheaper to administer, overall, in areas where mixed S. mansoni and S. haematobium infections are common.
The benzimidazoles Table II summarizes the helminthiases which are susceptible to this important group ofcompounds. Clinical application has mostly been in the context of intestinal, and to a lesser extent systemic, nematode infections;4 recently, use in some systemic cestode infections has also received a great deal of attention (see below). Success rates of up to 100% have been documented in small-intestinal (hookworm, Ascaris lumbricoides, and Strongyloides stercoralis) and colorectal (Trichuris trichiura and Enterobius vermicularis) infections.9`" A high degree of efficacy has also been reported in Capillaria philippinensis infection.'2"3 Two recent outbreaks of trichinellosis (trichinosis) -a systemic nematode infection -in France, which were caused by ingestion of infected horse-meat, apparently responded satisfactorily to albendazole.'4 Recent unpublished evidence from Thailand indicates a good response in Gnathostoma spinigerum infection. 4 While cutaneous larva migrans is rapidly cured with albendazole chemotherapy, visceral larva migrans responds far less favourably (see below).
The usual daily dose(s) of the benzimidazole compounds in the intestinal nematodiases is:4 mebendazole 100 mg twice daily (3-4 days), albendazole 400 mg daily (1 -3 days), and thiabendazole 1.5 g twice daily for 3 days; longer courses have been used for C. philippinensis infection. Significantly higher doses (and longer regimens) are recommended for systemic nematodiases, and this applies especially to mebendazole -which is poorly absorbed from the small-intestine. [6] [7] [8] [9] [10] [11] [12] months.35-41. Annual re-treatment must be provided, however, until the adult worms are dead. Furthermore, the severe side effects -manifested in both anterior and posterior chambers of the eyewhich were associated with the formerly used compound DEC (2-3 mg/kg three times daily for 21 days) are very unusual.42-47 Those reactions which have been reported are ofminor importance; the most common is a temporary aggravation of pruritus and rash. (When macrofilaricidal activity is required, suramin is still used but has potentially serious side effects.)
Oxamniquine and metriphonate
The advantage of these two agents over praziquantel is one of cost (Table I ). Many studies have compared the efficacy ofoxamniquine (a quinolone compound) with praziquantel in S. mansoni infection; most document comparable cure-rates and similar rates of reduction in the faecal eggexcretion.45' The optimal dose-regimen varies with the geographical region in which the S. mansoni infection was acquired. Rarely oxamniquine produces fever and/or epileptic fits. A significant problem has emerged, however -in Kenya, Liberia and Brazil, there is evidence of oxamniquine-resistant S. mansoni. Evidence that metriphonate (an organophosphorous compound) produces comparable cure-rates, and reduction in urinary S. haematobium egg-excretion when compared with praziquantel has also been produced. 52 Because it reduces the plasma cholinesterase concentration it should be used with caution in individuals who are likely to be frequently exposed to organophosphorous insecticides.
Some outstanding problems for the 1990s
Table IV summarizes some of the human helminthiases for which there is as yet no ideal chemotherapeutic agent, or regimen.
Systemic nematode infections
Unfortunately there are few published reports on the use of ivermectin in the human filariases apart from onchocerciasis (see above). Encouraging results have, however, been documented (using dose-regimens similar to those used for 0. volvulus infection) in Loa loa infection in Gabon;53 unfortunately, other studies have not confirmed these observations.3 Mebendazole has been used but with very limited success in loaiasis.5 Therefore, DEC is still widely used as a microfilaricide. As with onchocerciasis there is no satisfactory macrofilaricide. There are no published reports of the use of ivermectin in the lymphatic filariases; apart from DEC, metriphonate 10-15 mg/kg administered at 14 day intervals, is the only agent which has been shown to produce a significant reduction in the peripheral blood microfilarial concentration. Although there is now some evidence that DEC (and possibly metriphonate also) has limited properties as a macrofilaricidal agent; this requires further investigation. In dracontiasis (guinea-worm disease) a satisfactory chemotherapeutic agent simply does not exist; this fact is reflected in the numerous regimens which have been used -of which none is of proven A good deal of evidence has recently been accumulated indicating that albendazole is at least as effective as thiabendazole against intestinal S. stercoralis infection (see above).457 However, its use in the 'hyperinfection syndrome' (which is usually associated with immunosuppression)3 seems less satisfactory. This syndrome consists of widespread dissemination of larvae throughout most, or all, organs; severe dyspnoea caused by pulmonary infiltration, and paralytic ileus are common accompaniments. In addition, the migrating larvae transfer enterobacteriaceae (from the caecum and colon) to blood and central nervous system and this results in a subsequent bacteraemia and meningitis -the cerebrospinal fluid may in fact contain both S. stercoralis larvae and coliform bacteria. Unless satisfactory chemotherapy (which should include a suitable antibiotic) is immediately initiated as soon as a diagnosis is made, death ensues. The most effective of the benzimidazole compounds is probably cambendazole;5859 however, this agent has never been officially released for human use. Thiabendazole (25 mg/kg twice daily for 15 days) is of proven value; albendazole (400 mg daily for 15 days) has been studied to a far lesser extent. Ivermectin34 and cyclosporin A have not been adequately evaluated.
Some of the other human nematode infections also remain difficult to treat. Very few data exist on Angiostrongylus costaricensis and A. cantonensis (limited evidence suggests that thiabendazole is at least partly effective), and Anisakis sp. infections for example; with the latter infection (which is acquired by ingestion of raw or undercooked fishsushi and sashimi -and is common in Japan, and can be contracted in fish-bars in the USA and Europe), there is no satisfactory published evidence on the efficacy of any anthelmintic agent. 
Systemic trematode infections
Overall, praziquantel has proved of great value in intestinal and systemic trematode infections (see above); however Fasciola hepatica responds poorly to this agent.79'80 The benzimidazole compound, triclabendazole (at a dose of 10 mg/kg) has recently been used successfully;8' this observation requires confirmation.
Conclusions
The last 2-3 decades have seen significant advances in the management ofhuman helminthiases. The benzimidazoles, oxamniquine and metriphonate are sold at reasonable cost, and, with the exception of the poorest Third-World countries, are now widely available. Praziquantel remains a relatively expensive chemotherapeutic agent in most (but not all) countries. Albendazole, ivermectin, and metriphonate are available but only on a named-patient basis in the UK (Table I) . Despite these major advances, there are, however, several nematode, cestode and trematode infections for which safe and effective chemotherapy is still required; meanwhile the older agents (and also surgery) must still be employed.
An ideal broad-spectrum anthelmintic remains a long way off. Such a compound would be: (i) effective against all intestinal and systemic helminths, (ii) 100% effective when given as a singledose, (iii) safe in pregnancy and infancy as well as in healthy adults, (iv) stable at high (and low) ambient temperatures, and (v) low in cost.
There is, therefore, no room whatsoever for complacency in the chemotherapy of human helminthiases in the years ahead.
